Katritsis Demosthenes G, Ioannidis John P A
Department of Cardiology, Athens Euroclinic, Athens, Greece.
Circulation. 2005 Jun 7;111(22):2906-12. doi: 10.1161/CIRCULATIONAHA.104.521864. Epub 2005 May 31.
Percutaneous coronary intervention (PCI) has been shown to improve symptoms compared with conservative medical treatment in patients with stable coronary artery disease (CAD); however, there is limited evidence on the effect of PCI on the risk of death, myocardial infarction, and subsequent revascularization. Therefore, we performed a meta-analysis of 11 randomized trials comparing PCI to conservative treatment in patients with stable CAD.
A total of 2950 patients were included in the meta-analysis (1476 received PCI, and 1474 received conservative treatment). There was no significant difference between the 2 treatment strategies with regard to mortality, cardiac death or myocardial infarction, nonfatal myocardial infarction, CABG, or PCI during follow-up. By random effects, the risk ratios (95% CIs) for the PCI versus conservative treatment arms were 0.94 (0.72 to 1.24), 1.17 (0.88 to 1.57), 1.28 (0.94 to 1.75), 1.03 (0.80 to 1.33), and 1.23 (0.80 to 1.90) for these 5 outcomes, respectively. A possible survival benefit was seen for PCI only in trials of patients who had a relatively recent myocardial infarction (risk ratio 0.40, 95% CI 0.17 to 0.95). Except for PCI during follow-up, there was no significant between-study heterogeneity for any outcome.
In patients with chronic stable CAD, in the absence of a recent myocardial infarction, PCI does not offer any benefit in terms of death, myocardial infarction, or the need for subsequent revascularization compared with conservative medical treatment.
对于稳定型冠状动脉疾病(CAD)患者,经皮冠状动脉介入治疗(PCI)已被证明与保守药物治疗相比可改善症状;然而,关于PCI对死亡、心肌梗死及后续血运重建风险影响的证据有限。因此,我们对11项比较稳定型CAD患者PCI与保守治疗的随机试验进行了荟萃分析。
共有2950例患者纳入荟萃分析(1476例接受PCI,1474例接受保守治疗)。在随访期间,两种治疗策略在死亡率、心源性死亡或心肌梗死、非致命性心肌梗死、冠状动脉搭桥术(CABG)或PCI方面无显著差异。采用随机效应模型,PCI组与保守治疗组相比,这5种结局的风险比(95%可信区间)分别为0.94(0.72至1.24)、1.17(0.88至1.57)、1.28(0.94至1.75)、1.03(0.80至1.33)和1.23(0.80至1.90)。仅在近期发生心肌梗死患者的试验中,PCI显示出可能的生存获益(风险比0.40,95%可信区间0.17至0.95)。除随访期间的PCI外,任何结局在研究间均无显著异质性。
对于慢性稳定型CAD患者,在近期未发生心肌梗死的情况下,与保守药物治疗相比,PCI在死亡、心肌梗死或后续血运重建需求方面无任何益处。